46 47 48 experiments to understand their functional consequences 1,2 . Identification of expression 49 quantitative trait loci (eQTLs) has been a powerful approach to infer downstream effects of 50 disease variants but the large majority remains unexplained. 3,4 . The analysis of DNA 51 methylation, a key component of the epigenome 5 , offers highly complementary data on the 52 regulatory potential of genomic regions 6,7 . However, a large-scale, combined analysis of 53 methylome and transcriptome data to infer downstream effects of disease variants is lacking. 54 Here, we show that disease variants have wide-spread effects on DNA methylation in trans 55 that likely reflect the downstream effects on binding sites of cis-regulated transcription 56 factors. Using data on 3,841 Dutch samples, we detected 272,037 independent cis-meQTLs 57 (FDR < 0.05) and identified 1,907 trait-associated SNPs that affect methylation levels of 58 10,141 different CpG sites in trans (FDR < 0.05), an eight-fold increase in the number of 59 downstream effects that was known from trans-eQTL studies 3,8,9 . Trans-meQTL CpG sites 60 are enriched for active regulatory regions, being correlated with gene expression and overlap 61
Most disease associated genetic risk factors are non-coding, making it challenging to design
We subsequently studied the nature of these trans-meQTLs. Using high-resolution Hi-C data 10 , 140 we identified 720 SNP-CpG pairs (including 402 CpG sites and 172 SNPs) among the trans-141 meQTLs that overlapped with an inter-chromosomal contact, which is 2.9-fold more frequent than 142 expected by chance (P = 3.7 x 10 -126 , Figure 3c, d) . These Hi-C inter chromosomal enrichments 143 were not confounded due to SNPs that gave trans-meQTLs on many CpG sites (i.e. trans-bands): 144 when removing those trans-meQTLs from the analysis, Hi-C enrichments remained highly 145 significant (P = 1.7x10 -61 ). This indicates that some relationships between SNPs and CpGs in trans 146 are explained by inter-chromosomal contacts. In order to characterize the 720 SNP-CpG pairs 147 overlapping with inter-chromosomal contacts, we performed motif enrichments using three motif 148 enrichment analyses (Homer, PWMEnrich, DEEPbind) 21- 23 . These analyses identified that the 402 149 CpG sites frequently overlapped with CTCF, RAD21 and SMC3 binding sites (P = 2.3x10 -5 , P = 150 3.5x10 -5 and P = 5.1x10 -5 , respectively), factors known to affect chromatin architecture 24,25 . This 151 finding was confirmed by incorporating ChIP-Seq data on CTCF binding (1.8-fold enrichment, P 152 = 5.2x10-7). 153 We next tested whether the trans-meQTLs reflected the effect of differential transcription factor 154 (TF) binding of TFs that map close to the SNPs since TF binding has been implicated in 155 demethylation and loss of TF occupancy with remethylation 6,7 . This suggests that if a SNP allele 156 increases TF els in cis, that trans-meQTL effects are likely detectable, and that the SNP allele with at least 50 trans-meQTL effects (binomial test P < 0.05), suggesting that differential TF 163 binding may explain a substantial fraction of trans-meQTLs. 164 In order to explore this mechanism further, we combined ChIP-seq data on TF binding at CpGs 165 and cis-expression effects of SNPs to directly examine the involvement of TFs in mediating trans- 166 meQTLs. Among trait-associated SNPs influencing at least 10 CpGs in trans (n=305), we 167 identified 13 trans-meQTL SNPs with strong support for a role of TFs (Figure 4a ). 168 The most striking example was a locus on chromosome 4 (Figure 4b ), where two SNPs (rs3774937 169 and rs3774959, in strong LD) were associated with ulcerative colitis (UC) 26 . Top SNP rs3774937 170 was associated with differential DNA methylation at 413 CpG sites across the genome, 92% of 171 which showed the same direction of the effect, i.e. lower methylation associated with the risk allele 172 (binomial P=2.72x10 -69 ). Of those 380 CpG sites with lower methylation, 147 (38.7%) overlap 173 with a nuclear factor kappaB (NFKB) transcription factor binding site (2.75-fold enrichment, P = 174 5.3x10 -32 ), as based on ENCODE NFKB ChIP-seq data in blood cell types ( Figure 4c ). Three motif 175 enrichment analyses (Homer, PWMEnrich, DEEPbind) 21-23 also revealed an enrichment of NFKB 176 binding motifs for the 413 CpG sites thus corroborating the ChIP-seq results. Notably, SNP 177 rs3774937 is located in the first intron of NFKB1 and we found that the risk allele was associated 178 with higher NFKB1 expression ( Figure 4a ). Of the 413 trans-CpGs, 64 were eQTMs and revealed 179 a coherent gene network ( Figure 4d ) that was enriched for immunological processes related to 180 NFKB1 function 27 (Figure 4e ). Taken together, these results support the idea that the rs3774937 181 UC risk allele decreases DNA methylation in trans by increasing NFKB1 expression in cis.
182
The same analysis approach indicated that the trans-methylation effects of rs8060686 (linked to 183 various phenotypes including metabolic syndrome 28 and coronary heart disease 29 , and affecting 184 779 trans-CpGs) were due to CTCF which mapped 315 kb from rs8060686. We observed a strong 185 10 CTCF ChIP-seq enrichment with 603/779 trans-CpGs overlapping with CTCF binding (P =1.6x10 -186 232 ) and enriched CTCF motifs ( Figure 4a and Extended Data Fig. 5 ). Of these trans-CpGs, only13 187 have been observed previously in lymphocytes 18 . We observed that the risk allele increased DNA 188 methylation in trans by decreasing CTCF gene expression in cis. 189 We found another example of this phenomenon: 228 trans-meQTL effects of 4 SNPs on 190 chromosome 10, mapping near NKX2-3 and implicated in inflammatory bowel disease 26 , were 191 strongly enriched for NKX2 transcription factor motifs and associated with NKX2-3 expression.
192
The risk alleles decreased DNA methylation in trans at NKX2-3 binding sites by increasing NKX2-193 3 gene expression in cis (Extended Data Fig. 6 ).
194
One height locus 30 contained 4 SNPs which influence 267 trans-CpGs and implicate ZBTB38 195 (Extended Data Fig. 7) . In contrast to the aforementioned TFs that are transcriptional activators,
196
ZBTB38 is a transcriptional repressor 31,32 and its expression was positively correlated with 197 methylation in trans, in line with our observation that eQTMs in repressed regions are enriched 198 for positive correlations. Finally, the trans-methylation effects of rs7216064 (64 trans-CpGs), 199 associated with lung carcinoma 33 , preferentially occurred at regions binding CTCF, while the SNP 200 was located in the BPTF gene, known to occupy CTCF binding sites 34 (Extended Data Fig. 8 ).
gene expression in cis, whereas only 4.5% of the GWAS SNPs that do not give trans-meQTLs 208 affect TF gene expression in cis (Fisher's exact P = 6.6 x 10-13). 209 Here we report that one third of known disease-and trait-associated SNPs has downstream 210 methylation effects in trans, often affecting multiple regions across the genome. The biological 211 mechanism underlying trans-meQTLs often involves a local effect on the transcriptional activity 212 of nearby TFs that affects DNA methylation at distal binding sites of the corresponding TFs. The 213 direction of downstream methylation effects is remarkably consistent for each SNP and indicates 214 that decreased DNA methylation is a signature of increased binding of transcriptional activators.
215
Our study reveals previously unrecognized functional consequences of disease variants in non- The five cohorts used in our study are described briefly below. The number of samples per 285 cohort and references to full cohort descriptions can be found in Extended data table 1. LifeLines-DEEP 295 The LifeLines-DEEP (LLD) cohort 12 is a sub-cohort of the LifeLines cohort. 36 LifeLines is a 296 multi-disciplinary prospective population-based cohort study examining the health and health- to health and disease in the general population, with a special focus on multi-morbidity and 301 complex genetics. A subset of 1,500 LifeLines participants also take part in LLD 12 . For these 302 participants, additional molecular data is generated, allowing for a more thorough investigation 303 of the association between genetic and phenotypic variation. Rotterdam Study is to investigate the prevalence and incidence of and risk factors for chronic 324 diseases to contribute to a better prevention and treatment of such diseases in the elderly. 331 For each cohort separately, the genotype data were harmonized towards the Genome of the 332 Netherlands 40 (GoNL) using Genotype Hamonizer 41 and subsequently imputed per cohort using 333 Impute2 42 using GoNL 43 reference panel 43 (v5). Quality control was also performed per cohort. 334 We removed SNPs with an imputation info-score below 0.5, a HWE P-value smaller than 10 -4 , a 335 call rate below 95% or a minor allele frequency smaller than 0.05. These imputation and filtering 336 steps resulted in 5,206,562 SNPs that passed quality control in each of the datasets. 346 We remapped the 450K probes to the human genome reference (HG19) to correct for inaccurate 347 mappings of probes and identify probes that mapped to multiple locations on the genome. Details we used methylumi 46 to extract the data from the raw IDAT files. Next, we performed quality 356 control checks on the probes and samples, starting by removing the incorrectly mapped probes. 357 We checked for outlying samples using the first two principal components (PCs) obtained using the methylation data and to give us more power to detect meQTLs, we removed the first 366 components which were not affected by genetic information, the 22 first PCs, from the 367 methylation data using methodology we have successfully used in trans-eQTL 3,49 and meQTL 368 analyses before 44 .
Imputation and QC

345
Probe remapping and selection
369
RNA sequencing 370 Total RNA from whole blood was deprived of globin using Ambion's GLOBIN clear kit and 371 subsequently processed for sequencing using Illumina's Truseq version 2 library preparation kit. 
Cis-meQTL mapping 389
In order to determine the effect of nearby genetic variation on methylation levels (cis-meQTLs), 390 we performed cis-meQTL mapping using 3,841 samples for which both genotype data and 391 methylation data were available. To this end, we calculated the Spearman rank correlation and 392 corresponding P-value for each CpG-SNP pair in each cohort separately. We only considered 393 CpG-SNP pairs located no further than 250kb apart. The P-values were subsequently 394 transformed into a Z-score for meta-analysis. To maximize the power of meQTL detection, we 395 performed a meta-analysis over all datasets by calculating an overall, joint P-value using a 396 weighted Z-method. A comprehensive overview of this method has been described previously 55 .
20
To detect all possible independent SNPs regulating methylation at a single CpG-site we 398 regressed out all primary cis-meQTL effects and then ran cis-meQTL mapping for the same 399 CpG-site to find secondary cis-meQTL. We repeated that in a stepwise fashion until no more 400 independent cis-meQTL were found.
401
To filter out potential false positive cis-meQTLs caused by SNPs affecting the binding of a probe 402 on the array, we filtered the cis-meQTLs effects by removing any CpG-SNP pair for which the 403 SNP was located in the probe. In addition, all other CpG-SNP pairs for which the SNP was 404 outside the probe, but in LD (R 2 > 0.2 or D' > 0.2) with a SNP inside the probe were also 405 removed. We tested for LD between SNPs in the probe and in the surrounding cis area in the 406 individual genotype datasets, as well as in GoNL v5, in order to be as strict as possible in 407 marking a QTL as true positive.
408
To correct for multiple testing, we empirically controlled the false discovery rate (FDR) at 5%.
409
For this, we compared the distribution of observed P-values to the distribution obtained from 410 performing the analysis on permuted data. Permutation was done by shuffling the sample 411 identifiers of one data set, breaking the link between, e.g., the genotype data and the methylation 412 or expression data. We repeated this procedure 10 times to obtain a stable distribution of P-413 values under the null distribution. The FDR was determined by only selecting the strongest effect 414 per CpG 55 in both the real analysis and in the permutations (i.e. probe level FDR < 5%).
415
Cis-eQTL mapping 416
For a set of 2,116 BIOS samples we had also generated RNA-seq data. We used this data to 417 identify cis-eQTLs. Cis-eQTL mapping was performed using the same method as cis-meQTL 418 mapping. Details on these eQTLs will be described in a separate paper (Zhernakova et al, in 419 preparation). To identify associations between methylation levels and expression levels of nearby genes (cis-422 eQTMs), we first corrected our expression and methylation data for batch effects and covariates 423 by regressing out the PCs and regressing out the identified cis-meQTLs and cis-eQTLs, to ensure 424 only relationships between CpG sites and gene expression levels would be detected that were not 425 attributable to particular genetic variation or batch effects. We mapped eQTMs in a window of 426 250Kb around the TSS of a transcript. Further statistical analysis was identical to the cis-meQTL 427 mapping. For this analysis we were able to use a total of 2,101 samples for which both genetic, 428 methylation and gene expression data was available. To correct for multiple testing we controlled 429 the FDR at 5%, the FDR was determined by only selecting the strongest effect per CpG 55 in both 430 the real analysis and in the permutations.
431
Trans-meQTL mapping 432 To identify the effects of distal genetic variation with methylation (trans-meQTLs) we used the 433 same 3,841 samples that we had used for cis-meQTL mapping. To focus our analysis and limit 434 the multiple testing burden, we restricted our analysis to SNPs that have been previously found 435 to be significantly correlated to traits and diseases at a P < 5x10 -8 . We extracted these SNPs from 436 the NHGRI genome-wide association study (GWAS) catalogue, used recent GWAS studies not 437 yet in the NHGRI GWAS catalogue and studies on the Immunochip and Metabochip platform 438 that are not included in the NHGRI GWAS catalogue (Extended Data Table 1 ). We compiled 439 this list of SNPs in December 2014. Per SNP we only investigated CpG sites that mapped at least 440 5 Mb from the SNP or on other chromosomes. Before mapping trans-meQTLs, we regressed out 441 the identified cis-meQTLs to increase the statistical power of trans-meQTL detection (as done 442 previously for trans-eQTLs 3 ) and to avoid designating an association as trans that may be due to 443 22 long-range LD (e.g. within the HLA region). To ascertain the stability of the trans-meQTLs we 444 also performed the trans-mapping on the non-corrected data and the methylation data corrected 445 for cell-type proportions. In addition, we performed meQTL mapping on SNPs known to 446 influence the cell type proportions in blood 19, 20 .
447
To filter out potential false positive trans-meQTLs due to cross-hybridization of the probe, we 448 remapped the methylation probes with very relaxed settings, identical to Westra et al. 55 , with the 449 difference that we only accepted mappings if the last bases of the probe including the SBE site 450 were mapped accurately to the alternative location. If the probe mapped within our minimal 451 trans-window, 5 Mb from the SNP, we removed the effect as being a false positive trans-452 meQTL. 453 We controlled for multiple testing by using 10 permutations. We controlled the false-discovery 454 rate at 5%, identical to the aforementioned cis-meQTL analysis. 456 To check if the trans-meQTL effects can also be found back on gene expression levels, we 457 annotated the CpGs with a trans-meQTL to genes using our eQTMs. Using the 2,101 samples 458 for which both genotype and gene expression data were available, we performed trans-eQTL 459 mapping, associating the SNPs known to be associated with DNA methylation in trans with their 460 corresponding eQTM genes. region of interest were more often overlapping with a ChIP-seq region than the other trans-480 meQTL probes. We collected all transcription factor called narrow peak files from the UCSC 481 genome browser to perform the enrichments. LD window that spans maximally 250Kb from the trans-meQTL SNP and had a minimal R 2 of 497 0.8. If a Hi-C contact between the SNP block and the CpG-site was indicated, we flagged the 498 region as a positive for Hi-C contacts. As a background, we used the combinations found in our 499 50 permutated trans-meQTL analyses, taking for each permutation the top trans-meQTLs that 500 were similar in size to the real analysis. This permitted us to empirically determine whether there 501 were significantly more Hi-C interactions in the real data as compared to the permutations. 502 eQTM direction prediction 503 We predicted the direction of the eQTM effects using both a decision tree and a naïve Bayes 504 model (as implemented by Rapid-miner 60 v6.3). We built the models on the strongest eQTMs 505 (i.e. those identified at a very stringent FDR <9.73x10 -6 ). For the decision tree we used a CpG-gene combinations, by randomly sampling a subset of the overrepresented negatively 513 correlating CpG-gene combination group. We chose to do so to circumvent labelling al eQTMs 514 as negative, since this is the class were the majority of the eQTMs are in.
455
Trans-eQTL mapping
515
In the models we used annotation from the CpG-site, namely: overlap with epigenomics roadmap 516 chromatin states, histone marks and relations between the histone marks, GC content 517 surrounding the CpG-site and relative locations from the CpG-site to the transcript.
518
DEPICT
519
To investigate whether there was biological coherence in the trans-meQTLs identified, we 520 performed gene-set enrichment analysis for each genetic risk factor that was showing at least 10 521 trans-meQTL effects. To do so, we adapted DEPICT 27 , a pathway enrichment analysis method 522 that we previously developed for GWAS. Instead of defining loci with genes by using top 523 associated SNPs, we used the eQTM information to link CpGs to genes. Within DEPICT gene 524 set enrichment, significance is determined by using matched sets of permuted loci (in terms of 525 numbers of genes per locus) that have been identified using simulated GWAS. Subsequent 526 pathway enrichment analysis was conducted as described before, and significance was 527 determined by controlling the false discovery rate at 5%. 
